Introduction
The enhanced prevalence of infectious diseases threatens world population. Although tuberculosis appeared as a curable disease for years, it is regaining importance due to the multidrug resistance. 1, 2 Worldwide statistics on tuberculosis surprisingly reveals that, nearly one-third of the world's population is infected with tuberculosis, with approximately eight million new patients every year. 3 A major issue is the increase of multi-drug resistant tuberculosis (MDRTB)
giving rise to the disease expensive and incurable especially in immunodeficient subjects such as AIDS patients. 4 Hence, there is an increased demand to develop new antituberculosis agents effective against pathogens resistant to current treatment. Human immunodeficiency virus type 1 (HIV-1) has been recognized to be responsible for transmission and progress of acquired immune deficiency syndrome (AIDS). 5 There are many targets for anti -HIV drug development due to the unique nature of the replication of HIV-1. Of these target macromolecules, reverse transcriptase (RT) plays an essential role in the replicative cycle of HIV-1. 6 A key step for the replication and spread of the virus requires reverse transcription of the retroviral RNA to proviral DNA by the enzyme reverse transcriptase (RT). 7, 8 NNRTIs bind in a noncompetetive way to a unique region on the enzyme, namely nonsubstrate-binding site, resulting in alteration of its function and therefore achieving supression of HIV-1 replication with high selectivity. 9 Although combined use of nucleoside inhibitors of RT (NRTIs), non-nucleoside RT inhibitors (NNRTIs) and protease inhibitors (PIs) in the treatment of HIV infections may provide a dramatic recovery in most HIV-infected persons, resistance to the currently used agents remains as a clinical problem. 5 Consequenlty, there is still a need for novel and safe antiviral agents with potent and selective action which are also effective against mutant strains of HIV. Nevirapine, etravirine and efavirenz are representative examples of NNRTIs used in clinical practice today. 10 Ongoing studies for discovery of new antiviral agents then gave rise to novel types NNRTIs which include tetrahydroimidazobenzodiazepinthione (TIBO) compounds 11 , phenethylthiazolylthiourea (PETT) derivatives 11 , and 1H,3H-thiazolo [3,4-a] benzimidazoles (TBZs). 12 Recent studies on molecular modification of the latter (TBZs) revealed that, dismantling of the imidazole nucleus leading to the design of new 1,3-thiazolidin-4-one derivatives, maintained the molecular requirements for enzyme inhibition. 12 A literature search revealed that, 4-thiazolidinone derivatives may exhibit antibacterial 13-14 , antituberculosis, 15-17 antiviral 9, 12, [18] [19] [20] [21] [22] [23] and anticancer [24] [25] [26] [27] properties. According to Andres et al. 13 , 4-thiazolidinones may be considered as phosphate bioisosteres and therefore inhibit the bacterial enzyme MurB which is involved in the biosynthesis of peptidoglycan layer of the cell wall. 13 In
Results and Discussion
Chemistry Synthetic route to 1-27 is presented in Scheme 1. N-Benzoyl methionine 1 was prepared through the Schotten Baumann reaction procedure. 2-(Benzoylamino)-4-(methylthio)butyric acid methyl ester 2 was obtained by the reaction of N-benzoyl methionine 1 and methanol in the presence of a few drops of concentrated sulfuric acid. 2-(Benzoylamino)-4-(methylthio)butyric acid hydrazide 3 was prepared by heating compound 2 with hydrazine hydrate in methanol. By condensing the hydrazide 3 with methyl, ethyl, allyl and benzyl isothiocyanates in ethanol, 1-[2-(benzoylamino)-4-(methylthio)butyryl]-4-alkyl/arylalkyl thiosemicarbazides 4-7 were synthesized. N- [1-{[2-(3-alkyl/arylalkyl-4-oxo-1,3-thiazolidin-2-ylidene) hydrazino]carbonyl}-3-(methylthio)propyl]benzamides 8-11 were synthesized by refluxing the thiosemicarbazides 4-7 mentioned above and ethylbromoacetate in the presence of sodium acetate in absolute ethanol.
propyl}benzamide derivatives 12-27 were carried out by refluxing compounds 8-11 with aryl aldehydes in the presence of sodium methoxide in methanolic medium through Knoevenagel's reaction procedure .
The synthesized compounds were characterized by their IR, 1 H-NMR, 13 C-NMR, HR-EI and HR-FAB Mass Spectral data. The IR spectra of compound 1 was characterized by the presence of a new C=O absorption band at 1637 cm -1 . IR spectral data of compound 2 was also confirmed on the basis of IR spectral data in literature. 28 The band at 1650 cm -1 was attributed to the C=O streching band of hydrazide. The bands at 3315 cm -1 and 3267 cm -1 were assigned to NH 2 bands of hydrazide and they did not occur in the IR spectra of compounds 4-7. Absorption bands at 1212-1247 cm -1 , which were attributed to the C=S streching vibrations observed in the IR spectra of compounds 4-7. New C=O bands (1701-1725 cm -1 ) in the IR spectra of 1,3-thiazolidine-4-ones provided confirmatory evidence for ring closure. [29] [30] [31] The Ar-Cl and Ar-F absorption bands were observed in the IR spectra of the compounds 12-27. revealed the presence of two isomers as concluded from the -CONHN, -H 3 C-S-CH 2 -CH, endocyclic -CH 2 protons. As an appraisal the first singlet peak belongs to E isomer and the second one belongs to Z isomer and this may be explained on the basis of the difference in the relative stability of E and Z isomers formed due to the rotational restriction about the exocyclic N=C bond. 35 Compound 8 was selected as prototype and its 13 C-NMR spectrum was used for further support. Detecting -H 3 C-S-CH 2 -CH, -H 3 C-S-CH 2 -CH, endocyclic -CH 2 , both of the C=O and some of the aromatic C atoms as two peaks in stead of one provided confirmatory evidence for geometric isomerism.
The representative example compound 8 was fragmented via three prominent pathways to afford fragments at m/z 306.0809, m/z 145.0303 and m/z 232.0955 based on thioether moiety, -CONH bond cleavage, benzoyl cation as base peak and methylidene sulfonium cation, respectively, in accordance with literature. 35, 36 Compounds 9-11 were fragmented via quasimolecular ion by HR-FAB 37 .
The purity of compounds 4-27 was demonstrated by TLC and HPLC. There were no spots or peaks accounting for the starting compounds ; but for some compounds we observed more than one peak with the same UV spectra. By using HPLC-UV/DAD peak homogeneity was proved. Resonances assigned to the endocyclic -CH 2 -protons at the 5 th position of the 1,3-thiazolidine-4-one ring were not detected and instead of the mentioned proton's signal, two peaks with an integration of one proton symbolizing the methine proton of >C=CH-Ar moiety was observed between 7.23-8.11 ppm. 38 Considering the aromatic region of 1 H-NMR spectra of compounds 12-27 displayed signals of aromatic protons of arylidene segment as an evidence for the supposed structures. For further evidence to prove the geometric isomerism as a reason of rotational restriction of -N=C< and >C=CH-Ar bonds 13 C-NMR spectra of compound 13 was observed.
13
C-NMR data of the representative compounds 8 and 13, which were obtained using DEPT technique at 100 MHz, have also supported the carbon framework by discrimination of CH 3 , CH 2 , CH and quarternary carbons (C q ) (see experimental section). On the other hand, high accuracy between experimental and calculated 13 C chemical shifts were also observed ( Resonances due to the R 1 and R 2 groups of the compounds were recorded at expected values. The benzylic protons of compound 11 and compounds 23-27 were observed at 5.01-5.07 ppm and 4.80-5.03 ppm, respectively, and the benzylic protons of compound 11 could easily be differentiated from endocyclic CH 2 protons at the 5 th position of the 1,3-thiazolidine-4-one ring.
The representative example compound 14 fragmented via two prominent pathways to afford fragments by -CONH bond cleavage followed by dissociation of the thioether moiety and -NHN bond cleavage. 
Biological Activity
In view of the antimycobacterial and antiviral activity ascertained for similar 4-thiazolidinones, the synthesized compounds were evaluated for their antibacterial, antituberculosis and antiviral effects. Compounds 24-26 exhibited marginal activity (MIC = 250 µg/ml) against Staphylococcus aureus ATCC 29213, Bacillus subtilis A57 and Candida albicans A177. Ofloxacin, sulbactam + cefoperazone and/or netilmicin were used as positive reference standards to determine the sensitivity of one strain/isolate in each microbial species tested.
In vitro evaluation of antimycobacterial activity against M.tuberculosis H37Rv was carried out at the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF), National Institute of Allergy and Infectious Diseases, Southern Research Institute, Birmingham, Alabama, USA. Primary screen was conducted for all of the synthesized compounds 1-27 at 6.25 µg/ml against M.tuberculosis H37Rv in BACTEC 12B medium using the BACTEC 460 radiometric system. Rifampicin was used as the standard in the anti-tuberculosis activity screening. The most active derivative was identified as 27 with 90% inhibition of mycobacterial growth at 6.25 µg/ml. The remaining compounds showed marginal or no effect at this concentration.
Antiviral activities of the synthesized compounds were screened against various types of viruses in HEL, HeLa and Vero cell cultures. Anti-HIV and cytotoxicity data were also obtained with the compounds using the strains HIV-1 (III B ) For anti-HIV screening, nevirapine, delaviridine, efavirenz and zidovudine were used as the reference drugs. None of the tested compounds showed antiviral activity at subtoxic doses whereas some of them exhibited remarkable cytotoxic potential. Compounds 8, 13, 14, 23, 25 were evaluated for their anticancer activity against 60 human tumoral cell lines derived from nine different cancer types (non-small cell lung, colon, breast, ovarian, renal, prostate, CNS, leukemia and melanoma) by the National Cancer Institute (NCI). They did not exhibit anticancer activity having GI 50 values at a high concentration. Therefore, these compounds were not selected for further testing.
Experimental Section
General Procedures. All melting points (ºC, uncorrected) were determined using Büchi 530 melting point apparatus. Infrared spectra were recorded in KBr disc using BIO-RAD FTS-135, FT-IR spectrometer and expressed in wavenumber ν (cm -1 ). NMR spectra were obtained on a Bruker AVANC-DPX 400 NMR spectrometer at 400 MHz for 1 H and 100 MHz for 13 C-DEPT, the chemical shifts are expressed in δ (ppm) downfield from tetramethylsilane (TMS) using CDCl 3 , CDCl 3 -acetone and CDCl 3 -DMSO as solvent. High resolution electron impact and fast atom bombardment mass spectra were recorded on a Jeol JMS-700 instrument. The liquid chromatographic system, used in the present study, consisted of an Agilent technologies 1100 series instrument equipped with a quaternary solvent delivery system and a model Agilent series G-1315 A photodiode array detector. A Rheodyne syringe loading sample injector with a 50 µl sample loop was used for the injection of analytes. Chromatographic data were collected and processed using Agilent Chemstation Plus software. The separation was performed at ambient temperature, on a reversed phase NovoPak -C18 column (150 x 3.9 mm ; 5 µm particle size). All experiments were employed in the isocratic mode. The mobile phase was prepared by mixing methanol, acetonitrile and distilled water (50:10:40, v/v/v). This phase was filtered through a 0.45 µm membrane and degassed by ultrasonication, prior to use. Solvent delivery was employed at a flow rate of 1.0 ml.min -1 . Detection of the analytes was carried out at 210 nm. H 3 N 3 ) . N-{1-[[2-[5-(4-Chlorobenzylidene)-3-allyl-4-oxo-1,3-thiazolidin-2 Compounds exhibiting fluorescence were tested in the BACTEC 460 radiometric system. 51 Compounds effecting <90% inhibition in the primary screen (MIC > 6.25 µg mL −1 ) were not further evaluated. Compounds demonstrating at least 90% inhibition in the primary screen were re-tested at lower concentrations against M. tuberculosis H37Rv to determine the actual minimum inhibitory concentration (MIC) in the MABA. The MIC was defined as the lowest concentration inhibiting 99% of the inoculum.
2-(Benzoylamino)-4-(methylthio)butyric acid (1).
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N-{1-[[2-[5-(4-Fluorobenzylidene)-3-methyl-4-oxo-1,3-thiazolidin-2-ylidene]-hydrazino]-carbonyl]-3-(methylthio)propyl}benzamide (15). Synthesis of compound
Anticancer assay
A total of 60 human tumor cell lines derived from nine cancer types (non-small cell lung, colon, breast, ovarian, leukemia, renal, prostate, CNS, melanoma) formed the basis of this test. The tumor cells were cultured in RPMI1640 medium supplemented with 5% fetal calf serum and 2mM L-glutamine.The tumor cells are inoculated over a series of standard 96-well microtiter plates in 100 µl of medium. [52] [53] Density of the inoculum depended on the types of tumor cells and their growth characteristics. 54 These cells are then preincubated on the microtiter plate for 24h before adding the compounds. These were tested starting from DMSO solutions at five different concentrations (10 -4 , 10 -5 , 10 -6 , 10 -7 , 10 -8 M). After an incubation of the chemical agent for 48h with the tumor cell lines, sulforhodamine B (SRB) protein assay was used to estimate cell viability and growth. The cytotoxic effects are evaluated and the assay results and doseresponse parameters were calculated as described. 55 Details of this test system and the information derived from the activity pattern over all cell lines have been published. 54, [56] [57] 
